The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?

Published:2024-08 Issue:8 Volume:35 Page:683-685
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Migliaccio I.,Biganzoli L.^ORCID,Malorni L.^ORCID

Publisher

Elsevier BV

Reference17 articles.

1. The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy;De Santo;Cancers (Basel),2019

2. Novel endocrine therapies: what is next in estrogen receptor positive, HER2 negative breast cancer?;Corti;Cancer Treat Rev,2023

3. US Food and Drug Administration Approval Summary: elacestrant for estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer;Shah;J Clin Oncol,2024

4. A phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive. HER2-negative advanced breast cancer: SERENA-1 monotherapy results;Hamilton;Ann Oncol,2024

5. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial;Bidard;J Clin Oncol,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3